J W Chen

Suggest Changes
Learn More
OBJECTIVE This study aimed to demonstrate the non-inferiority of 50-week treatment with stepwise insulin intensification of basal-bolus insulin analogues [insulin detemir (IDet) and aspart (IAsp)](More)
AIMS Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve(More)
We thank Esposito et al. (1) for their comments regarding our analysis (2). It is indeed logical that baseline insulin regimen should have some power in predicting HbA1c change, perhaps particularly(More)
  • 1